Anteris Technologies (AVR) Registration filing summary

Company overview and business model

• Structural heart company focused on developing and commercializing innovative medical devices for aortic stenosis, with lead product DurAVR® THV, a single-piece biomimetic transcatheter heart valve system using proprietary ADAPT® tissue technology.

• DurAVR® THV system aims to address hemodynamic limitations of current TAVR devices, targeting both older and younger patients requiring durable, human-like valve replacements.

• Business model includes ongoing R&D, clinical trials, and strategic partnerships, with revenue currently derived from legacy tissue products and licensing agreements.

• Reorganization from Australian to Delaware corporation, with listing on NASDAQ and CDIs on ASX, and de-listing from ASX for the predecessor entity.

Financial performance and metrics

• Net sales for the nine months ended September 30, 2024: $2.2 million, down 1% year-over-year; net loss: $56.8 million, up 78% year-over-year.

• Year ended December 31, 2023: net sales $2.7 million, net loss $46.8 million; accumulated deficit as of September 30, 2024: $257.0 million.

• Cash and cash equivalents as of September 30, 2024: $10.6 million; negative cash flow from operations for the nine months ended September 30, 2024: $43.0 million.

• R&D expenses increased 79% to $38.1 million for the first nine months of 2024, reflecting investment in pivotal trial preparation and manufacturing scale-up.

• Company has a history of operating losses and expects to continue incurring losses for the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from the IPO will be used primarily for ongoing development of DurAVR® THV and preparation/enrollment of the pivotal trial, with remaining funds for working capital, general corporate purposes, and repayment of amounts owed under a convertible note facility.

• Proceeds are not sufficient to fund development through regulatory approval; additional capital will be required.